Vimarsana
Biggest News Aggregation in the World

Page 2 - Hiv Prep News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hiv Prep. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hiv Prep Today - Breaking & Trending Today

Meningococcal Vaccine Shows Benefit in STI Prevention - Vimarsana News

Meningococcal Vaccine Shows Benefit in STI Prevention

A new trial looks at the effect of doxycycline post-exposure prophylaxis and vaccination with meningococcal B vaccine on rates of sexually transmitted infections in men who have sex with men.

Researchers Voice 'Frustration' at Failed HIV Vaccine Trial - Vimarsana News

Researchers Voice 'Frustration' at Failed HIV Vaccine Trial

An interim analysis determined that the regimen was not effective in preventing infections, compared with placebo.

MSNBC Ayman June 4, 2024 02:56:00 - Vimarsana News

MSNBC Ayman June 4, 2024 02:56:00

Expound and how we can accomplish that as a society, both as journalism, public health officials? >> it's the essential work right now. monkeypox is still here. mpox dole here, hiv still a threat. stis are on the rise. we need to view sexual health care as health care. and not judge people for the ways in which they find pleasure. but offer to treat people, prevent disease no matter how people get that does it. we know from decades of hiv work, that works, if someone feels a stigma, or a strange relationship to their health care provider, they're less likely to get on the hiv prep, which can p...

USPSTF Issues Revised Draft HIV Prevention Recommendations - Vimarsana News

USPSTF Issues Revised Draft HIV Prevention Recommendations

Revised draft preexposure prophylaxis recommendations highlight the need for HIV prevention in all at-risk persons while insurers consider pricing tiers.

CAB-LA's Full Potential for HIV Prevention Hits Snags - Vimarsana News

CAB-LA's Full Potential for HIV Prevention Hits Snags

Problems with breakthrough infections, cost effectiveness, and complexity of follow-up are among the issues that need to be resolved to ease broader rollout of the long-acting injectable.